Dermapharm Holding SE (LON:0A5J)

London flag London · Delayed Price · Currency is GBP · Price in EUR
47.15
-0.15 (-0.32%)
At close: Jun 2, 2026
Market Cap2.01B +25.9%
Revenue (ttm)1.03B -1.4%
Net Income125.92M +39.2%
EPS2.34 +39.3%
Shares Out n/a
PE Ratio15.96
Forward PE16.13
Dividend0.77 (1.63%)
Ex-Dividend DateJun 27, 2025
Volume1,607
Open47.93
Previous Close47.30
Day's Range46.93 - 47.80
52-Week Range31.85 - 51.70
Beta0.86
Analystsn/a
Price Targetn/a
Earnings DateMay 13, 2026

About Dermapharm Holding SE

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company a... [Read more]

Industry Pharmaceutical Preparations
Founded 1991
Employees 3,503
Stock Exchange London Stock Exchange
Ticker Symbol 0A5J

Financial Performance

In 2025, Dermapharm Holding SE's revenue was 1.18 billion, a decrease of -1.43% compared to the previous year's 1.20 billion. Earnings were 132.41 million, an increase of 16.37%.

Financial numbers in EUR Financial Statements

News

EQS-DD: Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, buy

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 15.05.2026 / 14:00 CET/CEST The issuer is solely responsi...

19 days ago - Wallstreet:Online

Dermapharm Holding SE Earnings Call Transcript: Q1 2026

Q1 2026 delivered 1.1% revenue growth and a 7.5% rise in adjusted EBITDA, with margin expansion and strong free cash flow. All segments contributed, Mucos integration advanced, and the share buyback reduced free float to just above 10%.

21 days ago - Transcripts

Dermapharm Holding SE Slides: Q1 2026

Dermapharm Holding SE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.

21 days ago - Filings

Dermapharm Holding SE Quarterly report: Q1 2026

Dermapharm Holding SE has published its Q1 2026 quarterly earnings report on May 13, 2026.

21 days ago - Filings

EQS-AFR: Dermapharm Holding SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements

EQS Preliminary announcement financial reports: Dermapharm Holding SE / Preliminary announcement on the disclosure of financial statements Dermapharm Holding SE: Preliminary announcement of the public...

4 weeks ago - Wallstreet:Online

Dermapharm Holding SE Earnings Call Transcript: Q4 2025

Revenue and adjusted EBITDA for 2025 met guidance, with margin improvements and strong cash flow. Growth is expected in 2026 from M&A, branded products, and international expansion, while restructuring and portfolio optimization continue to drive efficiency.

2 months ago - Transcripts

Dermapharm Holding SE Annual report: Q4 2025

Dermapharm Holding SE has published its Q4 2025 annual report on March 31, 2026.

2 months ago - Filings

Dermapharm Holding SE Annual report: Q4 2025

Dermapharm Holding SE has published its Q4 2025 annual report on March 31, 2026.

2 months ago - Filings

Dermapharm Holding SE Earnings release: Q4 2025

Dermapharm Holding SE released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.

2 months ago - Filings

Dermapharm Holding SE Slides: Q4 2025

Dermapharm Holding SE has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 31, 2026.

2 months ago - Filings

Dermapharm Holding SE Earnings Call Transcript: Q3 2025

Branded pharmaceuticals drove growth in Q3 2025, with strong international and Alargo Pharma performance. Portfolio optimization and restructuring improved margins, while guidance for full-year revenue and EBITDA is expected to be met, supported by seasonal strength in Q4.

7 months ago - Transcripts

Dermapharm Holding SE Quarterly report: Q3 2025

Dermapharm Holding SE has published its Q3 2025 quarterly earnings report on November 13, 2025.

7 months ago - Filings

Dermapharm Holding SE Slides: Q3 2025

Dermapharm Holding SE has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 13, 2025.

7 months ago - Filings

Dermapharm Holding SE Quarterly report: Q2 2025

Dermapharm Holding SE has published its Q2 2025 quarterly earnings report on August 26, 2025.

10 months ago - Filings

Dermapharm Holding SE Slides: Q2 2025

Dermapharm Holding SE has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 26, 2025.

10 months ago - Filings